Vanda Pharmaceuticals recently announced that NEREUS (tradipitant) is now commercially available across the US for the prevention of vomiting induced by motion in adults, marking the first new prescription medicine approved for this condition in over 40 years. An innovative direct-to-consumer order platform is now available through nereus.us.

Motion sickness affects an estimated 65 to 78 million Americans—roughly 25 to 30 percent of adults—during everyday travel by car, plane, or boat. For decades, patients have had no meaningful new treatment options. That changes with NEREUS, an oral neurokinin-1 (NK-1) receptor antagonist that offers a modern, targeted approach to a problem that has long lacked innovation.

Mihael H. Polymeropoulos, M.D., President, CEO and Chairman, Vanda Pharma, said, "Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel. NEREUS is a selective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1) receptors that can block the vomiting center of the brain. We are excited to make this innovative therapy available through both traditional pharmacy channels and our new direct-to-consumer platform at nereus.us, giving travelers, families, and anyone affected by motion sickness convenient access to a long-awaited solution."

NEREUS is available now by prescription directly through nereus.us and retail pharmacies nationwide. Through the direct-to-consumer portal at nereus.us, patients with a valid prescription can access NEREUS at a cash-pay price of just USD 85 per dose.

Motion sickness may occur when the brain receives conflicting signals from the eyes, inner ear, and body while on motion. This sensory mismatch is believed to trigger the release of substance P, which activates NK-1 receptors in the Central Nervous System (CNS) and ultimately leads to nausea and vomiting. NEREUS works by blocking these receptors, interrupting the vomiting pathway.

The US Food and Drug Administration (FDA) approved NEREUS on December 30, 2025, following two pivotal phase 3 clinical trials—Motion Syros and Motion Serifos—conducted under real-world conditions on the open sea. Both studies demonstrated that NEREUS significantly prevented vomiting compared to placebo, confirming the drug's effectiveness in actual sea travel conditions. It is the first new prescription option for people with history of motion sickness in over 40 years. It employs a novel mechanism as a selective, high-affinity antagonist of human substance P/NK-1 receptors. It offers simple dosing with just one or two capsules a day taken approximately an hour before travel.